NCT06622187

Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies

Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies: a Double-blind Randomized Study

• Status: Enrolling By Invitation
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Hospital de Clinicas de Porto Alegre · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to evaluate the efficacy and safety of desmopressin to prevent bleeding after percutaneous renal graft biopsy in patients at high risk of bleeding. Researchers will compare desmopressin (DDAVP) to placebo to see if the drug reduces the risk of bleeding events related to kidney biopsy. Participants will receive intravenous desmopressin medication (100ml) or placebo (100mL of saline solution) before the kidney biopsy.

Conditions

• Bleeding
• Transplant, Kidney
• Desmopressin
• Kidney Biopsy

Interventions

Type	Name	Description
DRUG	Desmopressin (DDAVP)	Patients in the intervention group will receive desmopressin 0.3ug/kg administered as an intravenous infusion 1h before the proposed procedure
DRUG	Sodium Chloride	Patients in the control group will receive sodium chloride 0.9% 100mL administered as an intravenous infusion 1h before the proposed procedure

Timeline

• Start date: 2024-08-14
• Primary completion: 2026-06-01
• Completion: 2026-06-14
• First posted: 2024-10-02
• Last updated: 2025-09-11

Locations

1 site across 1 country: Brazil